While prophylactic use of meclizine is most effective in the treatment of
motion sickness, other factors such as patient age, and type, severity, and duration of
motion influence its effectiveness. It has been suggested that meclizine causes fewer anticholinergic effects than scopolamine. Meclizine was approved by the FDA in 1953.
For control of vertigo associated with vestibular system diseases:
Oral Dosage:
Adults and adolescents: The recommended dose is 25—100 mg/day PO in divided doses.